Abstract: Provided herein are methods of treating cancer (e.g., melanoma or RCC), which comprise administering to a human patient in need thereof: (a) a PD-1 antagonist; (b) a CTLA4 antagonist; and (c) lenvatinib represented by Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are kits containing such agents and uses of therapeutic combinations of such agents for the treatment of cancer.

Abstract: Provided herein are methods of treating a cancer, an infectious disease or infection, which comprise administering to a subject in need thereof a combination of agents: (a) an anti-human PD-1 antibody or antigen binding fragment thereof; (b) an anti-human CTLA4 antibody or antigen binding fragment thereof; and (c) an anti-human TIGIT antibody or antigen binding fragment thereof. Also provided are therapeutic combinations for use, pharmaceutical compositions and kits containing such agents for the treatment of a cancer, an infectious disease, or an infection.

Abstract: The present disclosure provides methods for detecting the genome-wide presence of methylated DNA and palindrome formation. The present disclosure also provides methods for specific enrichment of methylated DNA or DNA having a DNA palindrome. These methods have demonstrated that somatic palindromes and methylated DNA occur frequently and are widespread in human cancers. Individual tumor types have a characteristic non-random distribution of palindromes in their genome and a small subset of the palindromic loci are associate with gene amplification. The disclosed method can be used to define the plurality of genomic DNA palindromes and regions having methylated DNA associated with various tumor types and can provide methods for the classification of tumors, and the diagnosis, early detection of cancer as well as the monitoring of disease recurrence and assessment of residual disease.